Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 FDA Approves Herceptin as HER2 Breast Cancer Treatment | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

FDA Approves Herceptin as HER2 Breast Cancer Treatment

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genentech received approval from the FDA for Herceptin, a treatment regimen containing doxorubicin, cyclophosphamide, and paclitaxel, for the adjuvant treatment of HER2-positive node-positive breast cancer. Adjuvant therapy is given to women with early-stage (localized) breast cancer who have had initial treatment — surgery with or without radiation therapy — with the goal of reducing the risk of cancer recurrence and/or the occurrence of metastatic disease.

The approval was based on data from an interim joint analysis of more than 3,500 patients in two Phase III trials. These results showed that the addition of Herceptin to standard adjuvant therapy significantly reduced the risk of breast cancer recurrence, the primary endpoint of the studies, by 52% in women with HER2-positive breast cancer, compared to those patients who received standard adjuvant therapy alone.

After 3.5 years in the study, 87% of women treated with Herceptin plus chemotherapy were disease free, compared to 71% of women treated with chemotherapy alone. A survival analysis conducted after an average of 24 months showed a 33% reduction in the risk of death, or a 49% improvement in overall survival.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters